Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Major Depressive Disorder
NCT06247839Phase 3Recruiting
- Sponsor
- Sharmin Ghaznavi
- Start
- Sep 2024
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Sharmin Ghaznavi. Primary endpoints: Massachusetts General Hospital Rumination Questionnaire at 12 weeks, Resting-State Functional Connectivity at 12 weeks and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06247839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247839.